Drugs / TASONERMIN
TASONERMIN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00181025 | May 2004 → ? | sarcoma | Gustave Roussy, Cancer Campus, Grand Paris | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TASONERMIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107891 ↗ |
| Known as | Beromun | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107891 ↗ |
| Known as | FK 516 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107891 ↗ |
| Known as | Tasonermina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107891 ↗ |
| Known as | Tasonermine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00181025 ↗ |
| Modality | Protein / enzyme biologic | “1 mg tumor necrosis factor alpha (TNFa)” NCT00181025 ↗ |